Brokers Set Expectations for SLNO FY2025 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Soleno Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will earn ($1.97) per share for the year. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

Soleno Therapeutics (NASDAQ:SLNO) last posted its earnings results on Wednesday, November 6th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($1.22).

SLNO has been the subject of several other research reports. Oppenheimer upped their price target on shares of Soleno Therapeutics from $65.00 to $73.00 and gave the company an “outperform” rating in a report on Monday, October 28th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $74.00 price target on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $72.00 price objective on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $74.83.

Soleno Therapeutics Stock Performance

Shares of SLNO opened at $48.43 on Wednesday. The stock has a 50 day simple moving average of $48.62 and a 200 day simple moving average of $49.64. Soleno Therapeutics has a 52-week low of $36.61 and a 52-week high of $60.92. The firm has a market capitalization of $2.09 billion, a PE ratio of -14.59 and a beta of -1.47.

Insider Transactions at Soleno Therapeutics

In related news, insider Kristen Yen sold 2,340 shares of the company’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $46.18, for a total transaction of $108,061.20. Following the sale, the insider now owns 76,605 shares in the company, valued at approximately $3,537,618.90. This represents a 2.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Bhatnagar Anish sold 10,937 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total value of $496,649.17. Following the transaction, the chief executive officer now directly owns 708,616 shares of the company’s stock, valued at $32,178,252.56. This trade represents a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,360 shares of company stock worth $790,119 in the last three months. Insiders own 12.30% of the company’s stock.

Institutional Trading of Soleno Therapeutics

Large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in shares of Soleno Therapeutics by 21.5% in the 3rd quarter. Janus Henderson Group PLC now owns 4,081,099 shares of the company’s stock valued at $206,016,000 after purchasing an additional 722,226 shares during the period. Nantahala Capital Management LLC increased its position in Soleno Therapeutics by 27.9% during the second quarter. Nantahala Capital Management LLC now owns 3,082,107 shares of the company’s stock worth $125,750,000 after buying an additional 671,728 shares during the last quarter. FMR LLC raised its stake in Soleno Therapeutics by 6,048,754.5% in the third quarter. FMR LLC now owns 665,374 shares of the company’s stock valued at $33,595,000 after buying an additional 665,363 shares during the period. Westfield Capital Management Co. LP bought a new stake in Soleno Therapeutics in the third quarter valued at approximately $25,028,000. Finally, Wellington Management Group LLP lifted its position in shares of Soleno Therapeutics by 73.8% in the third quarter. Wellington Management Group LLP now owns 683,170 shares of the company’s stock valued at $34,493,000 after buying an additional 290,135 shares during the last quarter. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.